The internet keeps asking: “Can this drug do that?”
And every time the question comes up, the same thing happens—pharmacology sighs.
Not because the science is boring. Because the answer is rarely a simple yes/no, and the stakes are too high for shortc…

Stop the DIY drug patent search.
That’s the blunt takeaway from a recent DrugPatentWatch post highlighting an FTO (freedom-to-operate) opinion—and the real-world risk companies face when they treat patent searching like a quick Google exercise.
In the …

Stop the DIY Patent Search: The FTO Opinion That Could Save You From “Willful” Infringement
In pharma, the most expensive mistake is often the one you don’t realize you made—because you thought you were being careful.
A growing number of companies are …

Pharma procurement teams are being asked to do something that sounds simple—and is anything but: “Just buy the drug cheaper.”
But the real question isn’t unit price. It’s total cost.
In a world where drug spend is scrutinized line-by-line, procurement …

Pharma doesn’t always “win” new drugs. Sometimes it wins time.
Drug patent term extensions—those often-overlooked legal mechanisms that can push exclusivity out by years—are quietly one of the biggest levers in the industry’s financial model. And in a …

Generic drugmakers don’t “wait their turn.” They litigate their way to the starting line.
In the Hatch-Waxman era, the path to market for generics isn’t just a regulatory checklist—it’s a strategic chess match. And the most important moves often happ…

Drug patent cliffs don’t just erase revenue—they rewrite the rules of competition.
In the months leading up to loss of exclusivity, the market doesn’t wait for you to “be ready.” It moves. Formularies tighten. Payers demand differentiation. Procureme…

The “Side Effect” Conversation Isn’t About Side Effects—It’s About Signals.
For years, the pharmaceutical industry has treated adverse events like the inevitable tax you pay for innovation: something to document, manage, and—when possible—minimize. But…

A drug patent isn’t “worth” what the market says—it’s worth what it can survive.
In M&A, we love clean narratives: a pipeline, a valuation model, a headline number. But when the asset is a patent—especially one tied to a blockbuster or a near-ter…

Most NDAs Don’t Fail on Science. They Fail on Strategy.
In pharma, we love to talk about molecules—mechanisms, trial design, endpoints, and the elegance of the data. But anyone who’s shepherded an NDA knows the uncomfortable truth: the submission is …